Subscribe to Newsletter
Inside the Lab Microscopy and imaging, Digital and computational pathology, Oncology, Genetics and epigenetics

The Innovators 2019


Innovative continuous autofocus enables live view and control of slides anywhere in the world – instantly

Motic Digital Pathology debuted the FS-Live Telepathology System at USCAP 2019. Initially rolled out for Motic’s single-slide scanner, a mid-year update enabled FS-Live to load up to six slides at a time. Designed for affordable and efficient remote live frozen sections, ROSE, and FNA, FS-Live addresses workflow pain points for pathologists who serve multiple operating rooms or networked campuses.

The FS-Live system improves caseload efficiency by bringing the lab and operating room directly to the off-site pathologist, eliminating hours of travel and on-site time for experts. The continuous autofocus feature is an industry breakthrough innovation that eliminates the need for lengthy pre-mapping. Instead, FS-Live delivers a completely clear, in focus slide image within seconds. The system also leaves control entirely in the pathologist’s hands: change objectives, correct overstaining, measure, annotate, and drive the stage all from offsite. If users wish to send an image for a speedy second opinion, they can also capture snapshots of single layers or complete z-stacks without ever leaving the live interface.

Discover affordable telepathology and caseload efficiency with the high-resolution FS-Live system.

About Motic:
An innovator in the field of optics since 1988, Motic has never outsourced the production of its glass lenses for research microscopes or pathology scanners. Longstanding expertise and exceptional customer care serve as the foundation for the Motic Digital Pathology division’s mission of making digital pathology approachable for all.


The solution for automation, standardization, and total safety for biospecimen collection, transportation, and storage management

In 2006, formaldehyde was declared carcinogenic and mutagenic to humans by the International Agency for Research on Cancer. Despite this, in today’s labs and operating rooms, formaldehyde remains the standard fixative for collecting and storing biospecimens, exposing personnel to high levels of formaldehyde fumes. It has become crucial for hospitals and clinics to adopt precautions to ensure the safety of their personnel.

The “Zero Formalin Exposure” concept by Milestone revolutionizes personnel safety with the elimination of formaldehyde fumes in the operating room and histology lab, creating a healthier working environment. UltraSAFE is Milestone’s solution to formaldehyde reclassification, allowing users to continue using formalin in a safe manner. Using a unique, patented technology, buckets are automatically filled with formalin in an enclosed and vented chamber in the “dirty room,” preserving the biospecimen in fixative following the surgical excision.

UltraSAFE buckets are available in four standard sizes; 1, 3, 5, and 10 liters. All buckets have, built into the lid, an exclusive quadricuspid valve. This valve is specifically designed to prevent the escape of formalin fumes during operation and, at the same time, allows for formalin dispensing using UltraSAFE’s automatic filling. An additional cap attached to the valve seals the bucket for extra safety during transportation. On the bucket’s lid, a unique 2D barcode ensures biospecimen traceability. The UltraSAFE software can be used to associate this 2D barcode with the biospecimen ID number for full patient safety.

This allows for total operator safety, assures zero formalin exposure, and fulfills OSHA guidelines.

UltraSAFE is invaluable. It is an effective and immediate solution that addresses and eliminates formalin exposure for both histology and surgical personnel.


Paradigm shift from disease prognosis to prediction of chemotherapy benefit in HR+, HER2- early breast cancer

Guiding chemotherapy treatment decisions for HR+, HER2-early breast cancer is a challenging endeavour, given the lack of clear criteria to identify patients who respond to chemotherapy (1). Clinicians and pathologists have been using clinical pathological criteria, such as tumour grade and size among other prognostic parameters, to recommend chemotherapy only to those patients with poor prognosis.

Thanks to evidence from the practice-changing TAILORx trial, the Oncotype DX® test has been proven to predict chemotherapy benefit based on the patient’s individual tumour biology, thus establishing a fundamental paradigm shift in the decision - making for chemotherapy (2,3). The test identifies those few patients (20 percent) who will derive benefit from chemotherapy and the majority (80 percent) who won’t.

The Oncotype DX test is the third predictive marker after hormone-receptor (HR) status and HER2-receptor status to guide precise treatment decisions in early breast cancer (4).

Using RT-PCR technology on formalin-fixed tissue, the test quantifies the expression of a panel of 21 genes. Thanks to a high degree of standardisation, the test is very accurate and highly reproducible (5).

Major clinical guidelines and Health Technology Assessment bodies have recently updated their recommendations, thus making the test a standard of care in guiding chemotherapy treatment (6, 7, 8, 9, 10, 11).

The Oncotype DX test is now an essential tool for completing a pathology workup and providing a clear recommendation for every patient.

The Oncotype DX test is performed by Genomic Health, Inc., an Exact Sciences company.


DP3® delivers an integrated platform for Digital Pathology

The DP3 image management system provides a comprehensive suite of capabilities for in-house and collaborative clinical, educational, and research needs.

Corista provides a new level of interoperability for pathology, integrating WSI image scanning systems, image analytics and LIS/EHR platforms with a rich collaborative environment for clinicians, biotech, and pharmaceutical scientists.

DP3, the platform of choice for major medical organizations, leads the industry with fast, reliable, and ubiquitous access to the essential components of today’s digital pathology, including:

  • The industry standard in digital collaboration and consultation, Corista software is agnostic to image format, providing the most adaptability in the field.
  • Direct integration of the most popular quantitative image analytics systems.
  • Tools to anonymize, index, and manage images and cases for education and research.
  • A more complete way to manage cases of interest for teaching and clinical reference.

DP3 provides a more efficient and collaborative environment that can securely scale from single locations to multi-location and multi-organizational networks, extending the reach and speed of digital pathology applications.


Move beyond PD-L1 with powerful RNA models for comprehensive immune profiles from minimal tissue

Outside ImmunoPrism, there is no complete solution on the market today that characterizes the tumor microenvironment and generates multidimensional biomarkers from RNA data generated in your own laboratory. Even for difficult-to-measure cell types, such as M1 and M2 macrophages, the ImmunoPrism assay shows high sensitivity and specificity comparable to flow cytometry. The assay takes a new approach to immune cell characterization – leveraging targeted RNA sequencing and a database of immune Health Expression Models to deliver superior performance over other technologies.

The ImmunoPrism Kit enables immune profiling of any solid tumor tissue, including low-input FFPE samples, such as needle biopsies and microdissected tissue. Starting from RNA extraction through custom library generation for Illumina® sequencing, the kit includes full bioinformatic analysis and generates a comprehensive immune report for each sample. No additional expertise is required to make sense of the data. With clinical cohorts, the results may be used to generate a machine-learning optimized multidimensional biomarker, with full statistical analysis summarized in the ImmunoPrism Biomarker Report.

Cofactor’s ImmunoPrism Kit provides access to the most sensitive and specific method for immune cell quantification available for FFPE samples.

Learn more and download a sample report at:

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Early Breast Cancer Trialists’ Collaborative Group, Lancet, 379, 432 (2012).
  2. CE Geyer et al., NPJ Breast Cancer, 4, 37 (2018).
  3. JA Sparano et al., N Engl J Med, 379, 111 (2018).
  4. KV Ballman, J Clin Oncol, 33, 3968 (2015).
  5. FL Baehner, Ecancermedicalscience, 10, 675 (2016).
  6. MP Goetz et al., J Natl Compr Canc Netw, 17, 118 (2019).
  7. F Andre et al., J Clin Oncol, 37, 1956 (2019).
  8. HJ Burstein et al., Ann Oncol, 30, 1541 (2019).
  9. F Cardoso et al., Ann Oncol, [Epub ahead of print] (2019).
  10. IQWIG (2018). Available at:
  11. NICE (2018). Available at:
Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine